慢性肾脏病患者铁过载概述

Overview of iron overload in patients with chronic kidney disease

肾性贫血(renal anemia,RA)是慢性肾脏病的常见并发症,近年来的数据显示,肾性贫血的治疗现况并不乐观。铁剂治疗是改善肾性贫血的重要手段,然而,越来越多的研究证据表明,部分慢性肾脏病(chronic kidney disease,CKD)患者存在铁过载现象,铁过载带来的危害不容忽视。缺氧诱导因子-脯氨酸羟化酶抑制剂(hypoxia-inducible factor-proline hydroxylase inhibitors,HIF-PHI)作为治疗肾性贫血的新型药物,有望成为预防和治疗CKD患者铁过载的新选择。

Renal anemia is a common complication of chronic kidney disease(CKD),and recent data show that the current status of renal anemia treatment is not optimistic.Iron therapy is an important way to improve renal anemia,however,increasing evidences show that some patients with CKD have iron overload,and the dangers of iron overload cannot be ignored.Hypoxia-inducible factor-proline hydroxylase inhibitors(HIF-PHI),as novel drug for the treatment of renal anemia,is expected to be a new option for the prevention and treatment of iron overload in patients with CKD.